TP53 status and response to chemotherapy in breast cancer

Pathobiology

Volumn 75, Issue 2, 2008, Pages 132-139

  Bertheau, Philippe ^a   Espié, Marc ^a   Turpin, Elisabeth ^a   Lehmann, Jacqueline ^a   Plassa, Louis François ^a   Varna, Mariana ^a   Janin, Anne ^a   De Thé, Hugues ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Alkylating agents; Anthracycline; Breast cancer; Chemotherapy; p53; Taxanes; TP53

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; PACLITAXEL; PROTEIN P53; TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; DNA DAMAGE; DRUG RESPONSE; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; REVIEW;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 44949190413     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000123851     Document Type: Review

References (75)

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-1717.
2. Kaufmann M, von Minckwitz G, Rody A: Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast 2005;14:576-581.
3. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, Buchholz T, Meric F, Middleton L, Hortobagyi GN, Gonzalez-Angulo AM: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
4. Michaelis LC, Ratain MJ: Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006;6:409-414.
5. Bertheau P, Lerebours F, Mounier N, de Roquancourt A, Espie M, Clot P, Servant JM, Misset JL, Marty M, Janin A: Prognostic significance of a combined clinicopathologic score for response to primary systemic therapy in locally advanced breast cancer. Oncol Rep 2005;14:513-520.
6. Longley DB, Johnston PG: Molecular mechanisms of drug resistance. J Pathol 2005;205:275-292.
7. Brown JM, Attardi LD: The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005;5:231-237.
8. Collado M, Blasco MA, Serrano M: Cellular senescence in cancer and aging. Cell 2007;130:223-233.
9. Royds JA, Iacopetta B: p53 and disease: when the guardian angel fails. Cell Death Differ 2006;13:1017-1026.
10. Qian H, Wang T, Naumovski L, Lopez CD, Brachmann RK: Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 2002;21:7901-7911.
11. Inga A, Storici F, Darden TA, Resnick MA: Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence. Mol Cell Biol 2002;22:8612-8625.
12. Haupt S, Berger M, Goldberg Z, Haupt Y: Apoptosis - the p53 network. J Cell Sci 2003;116:4077-4085.
13. Yu J, Zhang L: The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005;331:851-858.
14. Lacroix M, Toillon RA, Leclercq G: p53 and breast cancer, an update. Endocr Relat Cancer 2006;13:293-325.
15. Soussi T, Wiman KG: Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007;12:303-312.
16. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006;10:501-514.
17. Vousden KH, Prives C: p53 and prognosis: new insights and further complexity. Cell 2005;120:7-10.
18. Toledo F, Wahl GM: Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006;6:909-923.
19. Chen X, Ko LJ, Jayaraman L, Prives C: p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev 1996;10:2438-2451.
20. Bertheau P, Turpin E, Rickman DS, EspiéM, de Reyniès A, Feugeas JP, Plassa LF, Soliman H, Varna M, de Roquancourt A, Lehmann-Che J, Beuzard Y, Marty M, Misset JL, Janin A, de ThéH: Exquisite sensitivity of TP53 mutant and basal breast cancers to a dosedense epirubicin-cyclophosphamide regimen. PLoS Med 2007;4:e90.
21. Tergaonkar V, Perkins ND: p53 and NF-kappaB crosstalk: IKKalpha tips the balance. Mol Cell 2007;26:158-159.
22. Tanaka T, Ohkubo S, Tatsuno I, Prives C: hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. Cell 2007;130:638-650.
23. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M: Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28:622-629.
24. Soussi T, Ishioka C, Claustres M, Béroud C: Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 2006;6:83-90.
25. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
26. Turpin E, Bieche I, Bertheau P, Plassa LF, Lerebours F, de Roquancourt A, Olivi M, Espie M, Marty M, Lidereau R, Vidaud M, de The H: Increased incidence of ERBB2 overexpression and TP53 mutation in inflammatory breast cancer. Oncogene 2002;21:7593-7597.
27. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bieche I, Varley J, Bignon Y, Uhrhammer N, Winqvist R, Jukkola-Vuorinen A, Niederacher D, Kato S, Ishioka C, Hainaut P, Borresen-Dale AL: The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12:1157-1167.
28. Willis A, Jung EJ, Wakefield T, Chen X: Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 2004;23:2330-2338.
29. Friedlander P, Haupt Y, Prives C, Oren M: A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. Mol Cell Biol 1996;16:4961-4971.
30. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, Vousden KH: Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996;15:827-838.
31. Soussi T: p53 alterations in human cancer: more questions than answers. Oncogene 2007;26:2145-2156.
32. Norberg T, Lennerstrand J, Inganas M, Bergh J: Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer 1998;79:376-383.
33. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, Sappino AP, Limacher IM, Bron L, Benhattar J, et al: A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995;92:3963-3967.
34. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J: An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005;102:13550-13555.
35. Bonnefoi H, Diebold-Berger S, Therasse P, Hamilton A, van de Vijver M, MacGrogan G, Shepherd L, Amaral N, Duval C, Drijkoningen R, Larsimont D, Piccart M: Locally advanced/inflammatory breast cancers treated with intensive epirubicin-based neoadjuvant chemotherapy: are there molecular markers in the primary tumour that predict for 5-year clinical outcome? Ann Oncol 2003;14:406-413.
36. Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD: p53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int J Cancer 2002;100:290-296.
37. Malamou-Mitsi V, Gogas H, Dafni U, Bourli A, Fillipidis T, Sotiropoulou M, Vlachodimitropoulos D, Papadopoulos S, Tzaida O, Kafiri G, Kyriakou V, Markaki S, Papaspyrou I, Karagianni E, Pavlakis K, Toliou T, Scopa C, Papakostas P, Bafaloukos D, Christodoulou C, Fountzilas G: Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Ann Oncol 2006;17:1504-1511.
38. Barbareschi M: Prognostic value of the immunohistochemical expression of p53 in breast carcinomas - a review of the literature involving over 9,000 patients. Appl Immunohistochem 1996;4:106-116.
39. Børresen-Dale AL: TP53 and breast cancer. Hum Mutat 2003;21:292-300.
40. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L: Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006;24:4236-4244.
41. Kim HA, Yom CK, Moon BI, Choe KJ, Sung SH, Han WS, Choi HY, Kim HK, Park HK, Choi SH, Yoon EJ, Oh SY: The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer. Breast 2008;17:19-26.
42. Takamura Y, Kobayashi H, Taguchi T, Motomura K, Inaji H, Noguchi S: Prediction of chemotherapeutic response by collagen gel droplet embedded culture-drug sensitivity test in human breast cancers. Int J Cancer 2002;98:450-455.
43. Herr I, Debatin KM: Cellular stress response and apoptosis in cancer therapy. Blood 2001;98:2603-2614.
44. Lowe SW, Ruley HE, Jacks T, Housman DE: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-967.
45. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-810.
46. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ Jr, Kohn KW: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57:4285-4300.
47. Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S: Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs. Biochim Biophys Acta 2004;1705:103-120.
48. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA, Lonning PE: Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 1996;2:811-814.
49. Geisler S, Lønning PE, Aas T, Johnsen H, Fluge O, Haugen DF, Lillehaug JR, Akslen LA, Børresen-Dale AL: Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001;61:2505-2512.
50. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganäs M, Meijervan Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-2162.
51. Rahko E, Blanco G, Soini Y, Bloigu R, Jukkola A: A mutant TP53 gene status is associated with a poor prognosis and anthracycline-resistance in breast cancer patients. Eur J Cancer 2003;39:447-453.
52. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavassoli M, Farrell PJ, Smith P, Lu X, Crook T: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003;3:387-402.
53. Xu Y, Yao L, Ouyang T, Li J, Wang T, Fan Z, Lin B, Lu Y, Xie Y: p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer. Clin Cancer Res 2005;11:7328-7333.
54. Bertheau P, Plassa F, EspiéM, Turpin E, de Roquancourt A, Marty M, Lerebours F, Beuzard Y, Janin A, de ThéH: Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002;360:852-854.
55. Bonnefoi H, Ducraux A, Movarekhi S, Pelte MF, Bongard S, Lurati E, Iggo R: p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients. Br J Cancer 2002;86:750-755.
56. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.
57. Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T: Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res 2006;12:159-168.
58. Johnson KR, Fan W: Reduced expression of p53 and p21WAF1/CIP1 sensitizes human breast cancer cells to paclitaxel and its combination with 5-fluorouracil. Anticancer Res 2002;22:3197-3204.
59. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E, Wenzel C, Schlagbauer-Wadl H, Mittlböck M, Gnant M, Steger G, Jakesz R: TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res 2000;6:50-56.
60. Noguchi S: Predictive factors for response to docetaxel in human breast cancers. Cancer Sci 2006;97:813-820.
61. Geisler S, Børresen-Dale AL, Johnsen H, Aas T, Geisler J, Akslen LA, Anker G, Lønning PE: TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res 2003;9:5582-5588.
62. Andersson J, Larsson L, Klaar S, Holmberg L, Nilsson J, Inganäs M, Carlsson G, Ohd J, Rudenstam CM, Gustavsson B, Bergh J: Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol 2005;16:743-748.
63. MacGrogan G, Mauriac L, Durand M, Bonichon F, Trojani M, de Mascarel I, Coindre JM: Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer 1996;74:1458-1465.
64. Niskanen E, Blomqvist C, Franssila K, Hietanen P, Wasenius VM: Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br J Cancer 1997;76:917-922.
65. Hamilton A, Piccart M: The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol 2000;11:647-663.
66. Lerebours F, Bieche I, Lidereau R: Update on inflammatory breast cancer. Breast Cancer Res 2005;7:52-58.
67. McGill G, Fisher DE: p53 and cancer therapy: a double-edged sword. J Clin Invest 1999;104:223-225.
68. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269.
69. Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R, Kroemer G: Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004;23:2825-2837.
70. Moreno CS, Matyunina L, Dickerson EB, Schubert N, Bowen NJ, Logani S, Benigno BB, McDonald JF: Evidence that p53-mediated cell-cycle-arrest inhibits chemotherapeutic treatment of ovarian carcinomas. PLoS ONE 2007;2:e441.
71. Bataille F, Rümmele P, Dietmaier W, Gaag D, Klebl F, Reichle A, Wild P, Hofstädter F, Hartmann A: Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 2003;56:286-292.
72. Burdelya LG, Komarova EA, Hill JE, Browder T, Tararova ND, Mavrakis L, DiCorleto PE, Folkman J, Gudkov AV: Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice. Cancer Res 2006;66:9356-9361.
73. Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, Newman J, Reczek EE, Weissleder R, Jacks T: Restoration of p53 function leads to tumour regression in vivo. Nature 2007;445:661-665.
74. Selivanova G, Wiman KG: Reactivation of mutant p53: molecular mechanisms and therapeutic potential. Oncogene 2007;26:2243-2254.
75. Gudkov AV, Komarova EA: The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003;3:117-129.